Frequent overexpression of aurora B kinase, a novel drug target, in non–small cell lung carcinoma patients
The DOI matches its Crossref record.
Abstract
The serine/threonine protein kinase aurora B, a key regulator of mitosis, is emerging as a novel drug target for cancer treatment. Aurora B overexpression has been previously documented by immunohistochemistry in several types of human tumors. We assessed aurora B expression in a series of 160 non–small cell lung cancer (NSCLC) samples (60% stage I, 21% stage II, 11% stage III, and 8% stage IV). In addition, we determined the expression of survivin and p16, two molecules also involved in cell cycle control. Aurora B was expressed selectively in tumor cells compared with normal epithelium. Aurora B expression was significantly correlated with expression of survivin in the nucleus (P < 0.0001), but not with expression of p16 (P = 0.134). High aurora B expression levels were significantly associated with older age (P = 0.012), male sex (P = 0.013), squamous cell carcinoma histology (P = 0.001), poor tumor differentiation grade (P = 0.007), and lymph node invasion (P = 0.037), in the subset of radically resected patients in our series. In addition, aurora B expression predicted shorter survival for the patients with adenocarcinoma histology, at both univariate (P = 0.020) and multivariate (P = 0.012) analysis. Survivin expression levels were neither associated with patient clinicopathologic characteristics nor with survival. However, expression of survivin in the nucleus was preferentially detected in stage I and II than in stage III and IV (P = 0.007) in the overall series of NSCLC samples. Taken together, our results suggest that aurora B may represent a valid target in NSCLC. [Mol Cancer Ther 2006;5(11):2905–13]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The functional diversity of Aurora kinases: a comprehensive review
Willems, E., Dedobbeleer, M., Digregorio, M., Lombard, A., Lumapat, P. N., & Rogister, B. (2018) · Cell Division · doi:10.1186/s13008-018-0040-6 · Cited by 416
Aurora Kinases as Anticancer Drug Targets
Gautschi, O., Heighway, J., Mack, P. C., Purnell, P. R., Lara, P. N., & Gandara, D. R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2179 · Cited by 386
Aurora‐A Kinase: A Potent Oncogene and Target for Cancer Therapy
Yan, M., Wang, C., He, B., Yang, M., Tong, M., Long, Z., Liu, B., Peng, F., Xu, L., Zhang, Y., et al. (2016) · Medicinal Research Reviews · doi:10.1002/med.21399 · Cited by 293
Modlin, I. M., Drozdov, I., & Kidd, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063364 · Cited by 164
“, chromogranin A/B (CHGA/CHGB: secretion], glutamate decarboxylase 1 [GAD1: GABA production] [25] and Aurora kinase B [AURKB: mitosis] [35] was undertaken.”
Aurora kinase targeting in lung cancer reduces KRAS-induced transformation
dos Santos, E. O., Carneiro-Lobo, T. C., Aoki, M. N., Levantini, E., & Bassères, D. S. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0494-6 · Cited by 64
“Interestingly, AURKA and AURKB expression levels have been used as diagnostic and prognostic markers in lung cancer [16–19, 52], suggesting that these kinases play a role in lung oncogenesis.”
Background
Metadata
- Authors
- Vischioni, B., Oudejans, J. J., Vos, W., Rodriguez, J. A., & Giaccone, G.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2006-11-01
- Volume
- 5
- Issue
- 11
- Pages
- 2905-2913
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2115945897
- Cited by
- 126
- References
- 0
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Frequent overexpression of aurora B kinase, a novel drug target, in non–small cell lung carcinoma patients. https://app.cochat.ai/papers/10.1158/1535-7163.mct-06-0301
- The paper
- Vischioni, B., Oudejans, J. J., Vos, W., Rodriguez, J. A., & Giaccone, G. (2006). Frequent overexpression of aurora B kinase, a novel drug target, in non–small cell lung carcinoma patients. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-06-0301
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.